Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Brain
Published in: Molecular Brain 1/2022

Open Access 01-12-2022 | Parkinson's Disease | Research

Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort

Authors: Alexander S. Mihaescu, Mikaeel Valli, Carme Uribe, Maria Diez-Cirarda, Mario Masellis, Ariel Graff-Guerrero, Antonio P. Strafella

Published in: Molecular Brain | Issue 1/2022

Login to get access

Abstract

The accumulation of beta amyloid in the brain has a complex and poorly understood impact on the progression of Parkinson’s disease pathology and much controversy remains regarding its role, specifically in cognitive decline symptoms. Some studies have found increased beta amyloid burden is associated with worsening cognitive impairment in Parkinson’s disease, especially in cases where dementia occurs, while other studies failed to replicate this finding. To better understand this relationship, we examined a cohort of 25 idiopathic Parkinson’s disease patients and 30 healthy controls from the Parkinson’s Progression Marker Initiative database. These participants underwent [18F]Florbetaben positron emission tomography scans to quantify beta amyloid deposition in 20 cortical regions. We then analyzed this beta amyloid data alongside the longitudinal Montreal Cognitive Assessment scores across 3 years to see how participant’s baseline beta amyloid levels affected their cognitive scores prospectively. The first analysis we performed with these data was a hierarchical cluster analysis to help identify brain regions that shared similarity. We found that beta amyloid clusters differently in Parkinson’s disease patients compared to healthy controls. In the Parkinson’s disease group, increased beta amyloid burden in cluster 2 was associated with worse cognitive ability, compared to deposition in clusters 1 or 3. We also performed a stepwise linear regression where we found an adjusted R2 of 0.495 (49.5%) in a model explaining the Parkinson’s disease group’s Montreal Cognitive Assessment score 1-year post-scan, encompassing the left gyrus rectus, the left anterior cingulate cortex, and the right parietal cortex. Taken together, these results suggest regional beta amyloid deposition alone has a moderate effect on predicting future cognitive decline in Parkinson’s disease patients. The patchwork effect of beta amyloid deposition on cognitive ability may be part of what separates cognitive impairment from cognitive sparing in Parkinson’s disease. Thus, we suggest it would be more useful to measure beta amyloid burden in specific brain regions rather than using a whole-brain global beta amyloid composite score and use this information as a tool for determining which Parkinson’s disease patients are most at risk for future cognitive decline.
Appendix
Available only for authorised users
Literature
1.
Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–45.PubMedCrossRef
2.
3.
Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature. 1988;334(6180):345–8.PubMedCrossRef
4.
Moustafa AA, Chakravarthy S, Phillips JR, Gupta A, Keri S, Polner B, Frank MJ, Jahanshahi M. Motor symptoms in Parkinson’s disease: a unified framework. Neurosci Biobehav Rev. 2016;68:727–40.PubMedCrossRef
5.
Marinus J, Zhu K, Marras C, Aarsland D, van Hilten JJ. Risk factors for non-motor symptoms in Parkinson’s disease. Lancet Neurol. 2018;17(6):559–68.PubMedCrossRef
6.
Biundo R, Weis L, Antonini A. Cognitive decline in Parkinson’s disease: the complex picture. npj Parkinson’s Dis. 2016;2(1):1–7.
7.
Ghadery C, Koshimori Y, Christopher L, Kim J, Rusjan P, Lang AE, Houle S, Strafella AP. The interaction between neuroinflammation and β-amyloid in cognitive decline in Parkinson’s disease. Mol Neurobiol. 2020;57(1):492–501.PubMedCrossRef
8.
9.
Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P, Zhang J. Parkinson Study Group DATATOP Investigators CSF tau and tau/Aβ42 predict cognitive decline in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(3):271–6.PubMedPubMedCentralCrossRef
10.
11.
Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, Growdon JH. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology. 2013;80(1):85–91.PubMedPubMedCentralCrossRef
12.
Kim J, Ghadery C, Cho SS, Mihaescu A, Christopher L, Valli M, Houle S, Strafella AP. Network patterns of beta-amyloid deposition in Parkinson’s disease. Mol Neurobiol. 2019;56(11):7731–40.PubMedCrossRef
13.
Melzer TR, Stark MR, Keenan RJ, Myall DJ, MacAskill MR, Pitcher TL, Livingston L, Grenfell S, Horne KL, Young BN, Pascoe MJ. Beta amyloid deposition is not associated with cognitive impairment in Parkinson’s disease. Front Neurol. 2019;10:391.PubMedPubMedCentralCrossRef
14.
Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, Barker RA, Collerton D, Taylor JP, Burn DJ. ICICLE-PD study group. Cognitive decline and quality of life in incident Parkinson’s disease: the role of attention. Parkinsonism Relat Disord. 2016;27:47–53.PubMedPubMedCentralCrossRef
15.
Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, Barker RA, Burn DJ. Stability of mild cognitive impairment in newly diagnosed Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88(8):648–52.PubMedCrossRef
16.
Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–44.PubMedCrossRef
17.
Broeders M, Velseboer DC, de Bie R, Speelman JD, Muslimovic D, Post B, de Haan R, Schmand B. Cognitive change in newly-diagnosed patients with Parkinson’s disease: a 5-year follow-up study. J Int Neuropsychol Soc. 2013;19(6):695–708.PubMedCrossRef
18.
Chung SJ, Park YH, Yoo HS, Lee YH, Ye BS, Sohn YH, Lee JM, Lee PH. Mild cognitive impairment reverters have a favorable cognitive prognosis and cortical integrity in Parkinson’s disease. Neurobiol Aging. 2019;78:168–77.PubMedCrossRef
19.
Pedersen KF, Larsen JP, Tysnes OB, Alves G. Natural course of mild cognitive impairment in Parkinson disease: a 5-year population-based study. Neurology. 2017;88(8):767–74. PubMedCrossRef
20.
Hall S, Öhrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Widner H, Decraemer H, Nägga K, Minthon L. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol. 2012;69(11):1445–52.PubMedCrossRef
21.
Irwin DJ, Lee VM, Trojanowski JQ. Parkinson’s disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci. 2013;14(9):626–36.PubMedPubMedCentralCrossRef
22.
Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C. CSF amyloid β 1–42 predicts cognitive decline in Parkinson disease. Neurology. 2010;75(12):1055–61.PubMedPubMedCentralCrossRef
23.
Gustot A, Gallea JI, Sarroukh R, Celej MS, Ruysschaert JM, Raussens V. Amyloid fibrils are the molecular trigger of inflammation in Parkinson’s disease. Biochem J. 2015;471(3):323–33.PubMedCrossRef
24.
25.
Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45(3):358–68.
26.
27.
Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA. The production of amyloid β peptide is a critical requirement for the viability of central neurons. J Neurosci. 2003;23(13):5531–5.PubMedPubMedCentralCrossRef
28.
Morley JE, Farr SA, Nguyen AD, Xu F. what is the physiological function of amyloid-Beta protein? J Nutr Health Aging. 2019;23(3):225–6.PubMedCrossRef
29.
Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ. Florbetaben Phase 3 Study Group. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015;11(8):964–74.
30.
Akhtar RS, Xie SX, Chen YJ, Rick J, Gross RG, Nasrallah IM, Van Deerlin VM, Trojanowski JQ, Chen-Plotkin AS, Hurtig HI, Siderowf AD. Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS ONE. 2017;12(5): e0177924.PubMedPubMedCentralCrossRef
31.
Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB. Amyloid imaging with 18F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210–7.PubMedCrossRef
32.
LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. J Biol Chem. 1994;269(38):23403–6.PubMedCrossRef
33.
Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord Off J Mov Disord Soc. 2008;23(15):2129–70.CrossRef
34.
35.
Yesavage JA. Geriatric depression scale. Psychopharmacol Bull. 1988;24(4):709–11.PubMed
36.
Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.
37.
Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord. 2008;23(7):1043–6.
38.
Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, Melzer TR, Kirwan J, Keenan R, Wells S, Porter RJ. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010;75(19):1717–25.PubMedCrossRef
39.
Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738–45.PubMedPubMedCentralCrossRef
40.
Fiorenzato E, Biundo R, Cecchin D, Frigo AC, Kim J, Weis L, Strafella AP, Antonini A. Brain amyloid contribution to cognitive dysfunction in early-stage Parkinson’s disease: the PPMI dataset. J Alzheimers Dis. 2018;66(1):229–37.PubMedCrossRef
41.
Ward JH Jr. Hierarchical grouping to optimize an objective function. J Am Stat Assoc. 1963;58(301):236–44.CrossRef
42.
Inguanzo A, Sala-Llonch R, Segura B, Erostarbe H, Abós A, Campabadal A, Uribe C, Baggio HC, Compta Y, Marti MJ, Valldeoriola F. Hierarchical cluster analysis of multimodal imaging data identifies brain atrophy and cognitive patterns in Parkinson’s disease. Parkinsonism Relat Disord. 2021;82:16–23.PubMedCrossRef
43.
Matias-Guiu JA, Díaz-Álvarez J, Ayala JL, Risco-Martín JL, Moreno-Ramos T, Pytel V, Matias-Guiu J, Carreras JL, Cabrera-Martín MN. Clustering analysis of FDG-PET imaging in primary progressive aphasia. Front Aging Neurosci. 2018;10:230.PubMedPubMedCentralCrossRef
44.
Uribe C, Segura B, Baggio HC, Abos A, Garcia-Diaz AI, Campabadal A, Marti MJ, Valldeoriola F, Compta Y, Tolosa E, Junque C. Cortical atrophy patterns in early Parkinson’s disease patients using hierarchical cluster analysis. Parkinsonism Relat Disord. 2018;50:3–9.PubMedCrossRef
45.
Leach LF, Henson RK. The use and impact of adjusted R2 effects in published regression research. Mult Linear Regres Viewp. 2007;33(1):1–1.
46.
Anderberg MR. Cluster analysis for applications: probability and mathematical statistics: a series of monographs and textbooks. Burlington: Academic Press; 2014.
47.
Bridges CC Jr. Hierarchical cluster analysis. Psychol Rep. 1966;18(3):851–4.CrossRef
48.
Couto B, Manes F, Montañés P, Matallana D, Reyes P, Velázquez M, Yoris A, Baez S, Ibáñez A. Structural neuroimaging of social cognition in progressive non-fluent aphasia and behavioral variant of frontotemporal dementia. Front Hum Neurosci. 2013;7:467.PubMedPubMedCentralCrossRef
49.
Knutson KM, Dal Monte O, Schintu S, Wassermann EM, Raymont V, Grafman J, Krueger F. Areas of brain damage underlying increased reports of behavioral disinhibition. J Neuropsychiatry Clin Neurosci. 2015;27(3):193–8.PubMedPubMedCentralCrossRef
50.
Wang YM, Zou LQ, Xie WL, Yang ZY, Zhu XZ, Cheung EF, Sørensen TA, Møller A, Chan RC. Altered grey matter volume and cortical thickness in patients with schizo-obsessive comorbidity. Psychiatry Res Neuroimaging. 2018;276:65–72.PubMedCrossRef
51.
52.
Buckner RL. The serendipitous discovery of the brain’s default network. Neuroimage. 2012;62(2):1137–45.PubMedCrossRef
53.
Palmqvist S, Schöll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, Blennow K, Landau S, Jagust W, Hansson O. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat Commun. 2017;8(1):1–3.CrossRef
54.
Adriaanse SM, Sanz‐Arigita EJ, Binnewijzend MA, Ossenkoppele R, Tolboom N, van Assema DM, Wink AM, Boellaard R, Yaqub M, Windhorst AD, van der Flier WM. Amyloid and its association with default network integrity in Alzheimer's disease. Hum Brain Mapp. 2014;35(3):779–91.
55.
56.
Sepulcre J, Grothe MJ, d’Oleire Uquillas F, Ortiz-Terán L, Diez I, Yang HS, Jacobs HI, Hanseeuw BJ, Li Q, El-Fakhri G, Sperling RA. Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nat Med. 2018;24(12):1910–8.PubMedPubMedCentralCrossRef
57.
Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, Førland MG, Tysnes OB, Larsen JP, Pedersen KF. CSF Aβ42 predicts early-onset dementia in Parkinson disease. Neurology. 2014;82(20):1784–90.PubMedCrossRef
58.
Bäckström DC, Domellöf ME, Linder J, Olsson B, Öhrfelt A, Trupp M, Zetterberg H, Blennow K, Forsgren L. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 2015;72(10):1175–82.PubMedCrossRef
59.
Buongiorno M, Antonelli F, Compta Y, Fernandez Y, Pavia J, Lomeña F, Ríos J, Ramírez I, García JR, Soler M, Cámara A. Cross-sectional and longitudinal cognitive correlates of FDDNP PET and CSF amyloid-β and Tau in Parkinson’s disease. J Alzheimers Dis. 2017;55(3):1261–72.PubMedCrossRef
60.
Caspell-Garcia C, Simuni T, Tosun-Turgut D, Wu IW, Zhang Y, Nalls M, Singleton A, Shaw LA, Kang JH, Trojanowski JQ, Siderowf A. Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. PLoS ONE. 2017;12(5): e0175674.PubMedPubMedCentralCrossRef
61.
Compta Y, Pereira JB, Ríos J, Ibarretxe-Bilbao N, Junqué C, Bargalló N, Cámara A, Buongiorno M, Fernández M, Pont-Sunyer C, Martí MJ. Combined dementia-risk biomarkers in Parkinson’s disease: a prospective longitudinal study. Parkinsonism Relat Disord. 2013;19(8):717–24.PubMedCrossRef
62.
Compta Y, Buongiorno M, Bargalló N, Valldeoriola F, Muñoz E, Tolosa E, Ríos J, Cámara A, Fernández M, Martí MJ. White matter hyperintensities, cerebrospinal amyloid-β and dementia in Parkinson’s disease. J Neurol Sci. 2016;367:284–90.PubMedCrossRef
63.
Modreanu R, Cerquera SC, Martí MJ, Ríos J, Sánchez-Gómez A, Cámara A, Fernández M, Compta Y. Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal τ and Aβ as well as dementia-risk in Parkinson’s disease. J Neurol Sci. 2017;373:223–9.PubMedCrossRef
64.
Parnetti L, Farotti L, Eusebi P, Chiasserini D, De Carlo C, Giannandrea D, Salvadori N, Lisetti V, Tambasco N, Rossi A, Majbour NK. Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson’s disease. Front Aging Neurosci. 2014;6:53.PubMedPubMedCentralCrossRef
65.
Terrelonge M, Marder KS, Weintraub D, Alcalay RN. CSF β-amyloid 1–42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. J Mol Neurosci. 2016;58(1):88–92.PubMedCrossRef
66.
67.
Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, Dalrymple-Alford JC, Anderson TJ. White matter microstructure deteriorates across cognitive stages in Parkinson disease. Neurology. 2013;80(20):1841–9.PubMedCrossRef
68.
Song SK, Lee JE, Park HJ, Sohn YH, Lee JD, Lee PH. The pattern of cortical atrophy in patients with Parkinson’s disease according to cognitive status. Mov Disord. 2011;26(2):289–96.PubMedCrossRef
69.
Wu L, Liu FT, Ge JJ, Zhao J, Tang YL, Yu WB, Yu H, Anderson T, Zuo CT, Chen L, Wang J. Clinical characteristics of cognitive impairment in patients with Parkinson’s disease and its related pattern in 18F-FDG PET imaging. Hum Brain Mapp. 2018;39(12):4652–62.PubMedPubMedCentralCrossRef
70.
Firbank MJ, Yarnall AJ, Lawson RA, Duncan GW, Khoo TK, Petrides GS, O'Brien JT, Barker RA, Maxwell RJ, Brooks DJ, Burn DJ. Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study. J Neurol Neurosurg Psychiatry. 2017;88(4):310–6.
71.
Hickok G, Poeppel D. The cortical organization of speech processing. Nat Rev Neurosci. 2007;8(5):393–402.PubMedCrossRef
72.
Jackson RL, Bajada CJ, Rice GE, Cloutman LL, Ralph MA. An emergent functional parcellation of the temporal cortex. Neuroimage. 2018;170:385–99.PubMedCrossRef
73.
Bullich S, Seibyl J, Catafau AM, Jovalekic A, Koglin N, Barthel H, Sabri O, De Santi S. Optimized classification of 18F-florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment. NeuroImage Clin. 2017;15:325–32.PubMedPubMedCentralCrossRef
74.
Doré V, Bullich S, Rowe CC, Bourgeat P, Konate S, Sabri O, Stephens AW, Barthel H, Fripp J, Masters CL, Dinkelborg L. Comparison of 18F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL® approaches: validation against histopathology. Alzheimers Dement. 2019;15(6):807–16.PubMedCrossRef
75.
Rowe CC, Doré V, Jones G, Baxendale D, Mulligan RS, Bullich S, Stephens AW, De Santi S, Masters CL, Dinkelborg L, Villemagne VL. 18F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging. 2017;44(12):2053–9.PubMedPubMedCentralCrossRef
76.
Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT. Correlation between decreased CSF α-synuclein and Aβ1–42 in Parkinson disease. Neurobiol Aging. 2015;36(1):476–84.PubMedCrossRef
77.
Heeman F, Hendriks J, Alves IL, Ossenkoppele R, Tolboom N, van Berckel BN, Lammertsma AA, Yaqub M. [11 C] PIB amyloid quantification: effect of reference region selection. EJNMMI Res. 2020;10(1):1.CrossRef
78.
Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C] PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446–52.
Metadata
Title
Beta amyloid deposition and cognitive decline in Parkinson’s disease: a study of the PPMI cohort
Authors
Alexander S. Mihaescu
Mikaeel Valli
Carme Uribe
Maria Diez-Cirarda
Mario Masellis
Ariel Graff-Guerrero
Antonio P. Strafella
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Molecular Brain / Issue 1/2022
Electronic ISSN: 1756-6606
DOI
https://doi.org/10.1186/s13041-022-00964-1

Other articles of this Issue 1/2022

Molecular Brain 1/2022 Go to the issue

Research

Assessments of prolonged effects of desflurane and sevoflurane on motor learning deficits in aged AppNL-G-F/NL-G-F mice

Research

Construction of a lncRNA-associated competing endogenous RNA regulatory network after traumatic brain injury in mouse

Research

Systemic injection of nicotinic acetylcholine receptor antagonist mecamylamine affects licking, eyelid size, and locomotor and autonomic activities but not temporal prediction in male mice

Research

The increased in vivo firing of pyramidal cells but not interneurons in the anterior cingulate cortex after neuropathic pain

Research

Spatiotemporal Pavlovian head-fixed reversal learning task for mice

Research

Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE)